Clinical trial · Interventional
Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Campath-1H in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)
NCT00081068CI-TRIAL-00008822withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well alemtuzumab works in treating patients with Waldenstrom's macroglobulinemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| alemtuzumab | Biological | Alemtuzumab | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Objective response
- measure
- Time to treatment failure
- measure
- Toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma) * Immunoglobulin (Ig) M, IgG, and IgA paraprotein * Measurable monoclonal paraprotein * Failed at least 1 prior first-line therapy (alkylator agent, nucleoside analogue, or rituximab) * CD52-positive tumor determined by either bone marrow immunohistochemistry or flow cytometry PATIENT CHARACTERISTICS: Age * Over 18 Performance status * ECOG 0-2 Life expectancy * At least 6 months Hematopoietic * Absolute neutrophil count ≥ 500/mm\^3 * Platelet count ≥ 25,000/mm\^3 Hepatic * SGOT ≤ 2.5 times upper limit of normal (ULN) * Bilirubin ≤ 2.5 times ULN Renal * Creatinine ≤ 2.5 mg/dL (\> 2.5 mg/dL allowed if due to disease) Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective double-method contraception during and for 6 months after study participation * No serious comorbid disease * No uncontrolled bacterial, fungal, or viral infection * No other active malignancy PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics * No prior alemtuzumab * More than 3 months since other prior monoclonal antibody therapy Chemotherapy * See Disease Characteristics * More than 21 days since prior chemotherapy Endocrine therapy * More than 21 days since prior steroid therapy Radiotherapy * More than 21 days since prior radiotherapy Surgery * Not specified
References
Publications (0)
Data not yet available
No reference posted for this study.